ADDED
The number of outstanding shares of the registrant s common shares as of February 11, 2026 was 354,318,198 .
BI-BLADE is a trademark of Medical Instrument Development Laboratories, Inc.
(including on the countries in which we do business and sectors in which we do business (including pharmaceuticals)) and counter-tariffs or other retaliatory measures imposed (or that may be imposed) on the U.S.
military action in Venezuela and the tensions between the U.S.
and Greenland, and other members of the North Atlantic Treaty Organization; and the anticipated separation from Bausch Health Companies Inc.
military action in Venezuela and the tensions between the U.S.
( BHC ), with BHC directly or indirectly holding 310,449,643 Bausch + Lomb common shares, which represents approximately 88% of the issued and outstanding common shares of Bausch + Lomb, as of February 11, 2026.
Segment revenues for the years 2025, 2024 and 2023 were as follows: 2025 2024 2023 (in millions) Amount Pct.
Vision Care $ 2,923 57 % $ 2,739 57 % $ 2,543 61 % Pharmaceuticals 1,284 25 % 1,209 25 % 836 20 % Surgical 894 18 % 843 18 % 767 19 % Total revenues $ 5,101 100 % $ 4,791 100 % $ 4,146 100 % Comparative segment information for 2025, 2024 and 2023 is further presented in Note 21, SEGMENT INFORMATION to our audited Consolidated Financial Statements.
PreserVision AREDS 3, a next-generation eye vitamin formulation, is anticipated to launch in 2026.
REMOVED
The number of outstanding shares of the registrant s common shares as of February 12, 2025 was 352,470,796 .
( BHC ), with BHC directly or indirectly holding 310,449,643 Bausch + Lomb common shares, which represents approximately 88.1% of the issued and outstanding common shares of Bausch + Lomb, as of February 12, 2025.
Bausch + Lomb understands that BHC continues to believe that completing the Separation, which may include the transfer of all or a portion of BHC s remaining direct or indirect equity interest in Bausch + Lomb to its shareholders (the Distribution ), the monetization of all or a portion of BHC s ownership interest in Bausch + Lomb, the sale of the Company (a Sale Transaction ) or a combination thereof, makes strategic sense and that BHC continues to evaluate all relevant factors and considerations related to completing the Separation, including those factors described in BHC s public filings.
Segment revenues for the years 2024, 2023 and 2022 were as follows: 2024 2023 2022 (in millions) Amount Pct.
Vision Care $ 2,739 57 % $ 2,543 61 % $ 2,369 63 % Pharmaceuticals 1,209 25 % 836 20 % 681 18 % Surgical 843 18 % 767 19 % 718 19 % Total revenues $ 4,791 100 % $ 4,146 100 % $ 3,768 100 % Comparative segment information for 2024, 2023 and 2022 is further presented in Note 21, SEGMENT INFORMATION to our audited Consolidated Financial Statements.
Biotrue multi-purpose solution helps prevent certain tear proteins from denaturing and fights germs for healthy contact lens wear.
A new line extension formulation, Lumify Preservative Free, for which the New Drug Application ( NDA ) was approved by the U.S.
Food and Drug Administration (the FDA ) in April 2024, began launching in the first quarter of 2025.
Blink OTC product line consists of a variety of eye drops and contact lens rewetting drops designed to provide immediate and long-lasting symptom relief.
In July 2023, we acquired the Blink OTC product line of eye and contact lens drops from Johnson Johnson Vision, which consists of Blink Tears Lubricating Eye Drops, Blink Tears Preservative Free Lubricating Eye Drops, Blink GelTears Lubricating Eye Drops, Blink Triple Care 2 Lubricating Eye Drops, Blink Contacts Lubricating Eye Drops and Blink-N-Clean Lens Drops (collectively, the Blink Product Line ).